文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

Acoramidis早期升高血清转甲状腺素蛋白独立预测TTR淀粉样心肌病生存改善

Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid Cardiomyopathy.
PubMed 文献 · J Am Coll Cardiol · 2025-01-01

ATTRibute-CM研究纳入557例ATTR-CM患者,评估acoramidis治疗早期血清转甲状腺素蛋白(sTTR)变化与全因死亡的关系。治疗28天内sTTR平均升高9.1 mg/dL并持续30个月,早期ΔTTR独立与全因死亡降低相关,且完全介导acoramidis对生存的获益。

要点

  • acoramidis治疗28天内sTTR平均升高9.1 mg/dL并持续30个月。
  • 早期ΔTTR每增加1 mg/dL,全因死亡风险降低(HR 0.96,95%CI 0.93-0.98,P=0.002)。
  • sTTR每增加5 mg/dL,全因死亡 odds 相对降低31.6%。

核心结论

  • acoramidis介导的早期sTTR升高在校正已知预测因素后仍独立与生存改善相关。
  • 早期sTTR变化可作为TTR稳定程度的标志物。

研究设计与样本

  • ATTRibute-CM(NCT03860935)3期研究的事后分析,纳入557例ATTR-CM患者。
  • 采用Kaplan-Meier生存评估、单变量和多变量建模分析全因死亡相关因素。

主要发现

  • acoramidis治疗28天内sTTR平均升高9.1 mg/dL,并持续整个30个月治疗期。
  • 基线sTTR≥20 mg/dL者总生存概率显著高于<20 mg/dL者(P<0.0001)。
  • 单变量分析中早期ΔTTR每增加1 mg/dL与全因死亡降低相关(HR 0.96,95%CI 0.93-0.98,P=0.002)。
  • 多变量分析校正TTR变异状态、基线NYHA心功能分级、基线国家淀粉样变性中心分期和基线sTTR后,早期ΔTTR仍独立与全因死亡降低相关(P<0.001)。
  • Bootstrap中介分析显示早期ΔTTR完全介导acoramidis对全因死亡概率的效应(平均因果中介效应=-0.117,P=0.002;平均直接效应=0.0366,P=0.448)。

关键数值与推荐

  • acoramidis治疗组中早期ΔTTR与全因死亡降低相关,安慰剂组无此关联。
  • 逻辑模型预测sTTR每增加5 mg/dL,全因死亡 odds 相对降低31.6%。

临床怎么用

  • 早期sTTR升高幅度可用于评估acoramidis对TTR的稳定程度。
  • 治疗28天时的sTTR变化有助于识别生存获益更明显的ATTR-CM患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acoramidis is a novel, high-affinity stabilizer that achieves ≥90% transthyretin (TTR) stabilization. The phase 3 study, ATTRibute-CM (Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy), met its primary hierarchical efficacy endpoint with mortality, morbidity, and functional components at 30 months. Stabilization of TTR (prealbumin) by acoramidis results in an immediate and sustained rise in serum transthyretin (sTTR) levels, but the association between this pharmacodynamic effect and all-cause mortality (ACM) has not been elucidated. OBJECTIVES: The purpose of this study was to assess the prognostic implication of acoramidis-mediated early change in sTTR and its relationship to ACM. METHODS: We evaluated sTTR levels in 557 participants with ATTR-CM from the ATTRibute-CM study population. For the Kaplan-Meier overall survival assessment, univariate and multivariate modeling were used to evaluate factors associated with ACM. Modeling and simulation analyses described acoramidis population pharmacokinetics. RESULTS: Treatment with acoramidis resulted in a sharp and significant early rise in sTTR levels (mean 9.1 mg/dL) within 28 days which was sustained throughout the 30-month treatment period. Participants with ≥20 mg/dL sTTR at baseline had significantly (P < 0.0001) greater overall survival probability than those with <20 mg/dL. An early increase in sTTR levels on day 28 of dosing (early ΔTTR) was associated with reduced ACM in univariate analysis (HR: 0.96 per 1 mg/dL increase in early ΔTTR; 95% CI: 0.93-0.98; P = 0.002). In the multivariate analysis, after adjusting for TTR variant status, baseline New York Heart Association functional class, baseline National Amyloidosis Centre stage, and baseline sTTR level, early ΔTTR remained independently associated with reduced ACM (P < 0.001). Bootstrap mediation analyses showed that early ΔTTR fully mediates the effect of acoramidis treatment on ACM probability (average causal mediation effect = -0.117; P = 0.002; average direct effect = 0.0366; P = 0.448). Logistic modeling demonstrated that among participants treated with acoramidis, early ΔTTR was associated with reduced ACM, whereas no such association was observed in participants treated with placebo. For every 5 mg/dL increase in sTTR levels, a logistic model predicted a 31.6% relative reduction in odds of ACM. CONCLUSIONS: Acoramidis-mediated early ΔTTR is independently associated with improved survival after adjusting for known predictors. This provides strong evidence for a direct association between a prompt and sustained increase in sTTR upon initiation of treatment with acoramidis and survival. Early changes in sTTR could be used as a marker of the degree of TTR stabilization. (Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy [ATTRibute-CM]; NCT03860935).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Maurer MS, Judge DP, Gillmore JD, et al. Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid Cardiomyopathy. J Am Coll Cardiol. 2025. PMID: 40398971. doi:10.1016/j.jacc.2025.03.542

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。